HealthTree Logo
search more_vert
App Logo
person Sign In / Create Account
Clinical Trial: Myeloma Checkpoint Inhibitor With or Without Lenalidomide
Posted: Aug 19, 2016
Clinical Trial: Myeloma Checkpoint Inhibitor With or Without Lenalidomide image

Checkpoint inhibitors are now entering myeloma clinical trials and are immunotherapy drugs that can be added to existing myeloma treatments. Multiple myeloma puts the brakes on the immune system and these type of immunotherapies remove that brake so the immune system can regain its ability to fight myeloma. Lenalidomide is known to enhance the immune system, so in this study, Genentech is determining whether MPDL3280A (Anti-Programmed Death Ligand 1 [aPD-L1] Antibody)  is most effective with or without lenalidomide. This is a phase I study that is open at 8 myeloma research centers around the United States. The trial objective is to enroll 46 patients.

To find this study on SparkCures, click here:

Anti PDL-1 Antibody Clinical Trial

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd). 

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube